Novartis announced long-term results from the ELIANA pivotal clinical trial of Kymriah® (tisagenlecleucel), the first-ever approved CAR-T cell therapy, in children and young adult patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL), with a maximum survival follow-up of 5.9 years. For the 79 patients treated with Kymriah in this study, the five-year overall survival (OS) rate was 55% (95% CI, 43-66), while the median event-free survival (EFS) for patients in remission within three months of infusion (n=65) was 43.8 months.
- Read more about Novartis five-year Kymriah® data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/novartis-five-year-kymriah-data-show-durable-remission-and-long-term-survival-maintained-in-children-and-young-adults-with-advanced-b-cell-all
No comments:
Post a Comment